30 closest matches · ranked by relevance
Neutropenia · Infection
Primary: Percentage of Participants Who Are Alive at 42 Days After Treatment and Have Had Microbial Response — 42.9; 41.7 percentage of participants — p=0.73
Breast Cancer · Non-Small Cell Lung Cancer · Ovarian Cancer
Primary: Percentage of Participants With Febrile Neutropenia (FN) — 8; 8; 15; 9 percentage of participants
Herpes Simplex
Primary: Number of Participants Experiencing Incidence of Nephrotoxicity, Defined as a Serum Creatinine ≥ 2 Times the Patient's Baseline — 2; 3 participants
Fever · Sweating · Hot Flashes
Primary: Number of Participants Who Became Afebrile Within 72 Hours of Starting Daptomycin. — 16 participants
Chemotherapy-induced Neutropenia
Primary: Duration of Severe Neutropenia in Cycle 1 — 0.9; 1.6; 1.1; 0.9 days
Chemotherapy-induced Neutropenia
Primary: DSN — 0.15; 0.36; 0.43; 0.29 days
Chemotherapy-induced Neutropenia
Primary: Double-Blind Phase: Duration of Severe Neutropenia in Cycle 1 — 1.0; 1.1 days
Chemotherapy-induced Febrile Neutropenia
Primary: Percentage of Participants With Febrile Neutropenia — 3.3; 1.9; 0.4; 0.5 percentage of participants
Schizophrenia
Primary: Change in White Blood Cell (WBC) (mm3) and Absolute Neutrophil Counts (ANC) (mm3) in Persons According to Presence of the DARC Null Allele. — 2755.1; 3079.9; 4360.6…
Non-Interventional Study
Primary: Percentage of Participants With Any Significant Comorbidities — 42.7 percentage of participants
Neutropenia
Primary: Duration of Severe Neutropenia (DSN) in Cycle 1 — 1.03; 0.44; 0.03; 0.31 days — p=0.296
Neutropenia
Primary: Blood Neutrophil Counts. — 4.48 10^9 per Liter — p=<0.05
Acute Myeloid Leukemia · Neutropenia · Bacteremia
Primary: Occurrence of Post-chemotherapy Bacteremia — 22; 81 Participants
Breast Cancer
Primary: Comparison of Cumulative Incidence of Anti-pegfilgrastim Antibodies (Binding and Neutralizing) to Pegfilgrastim Between Treatment Groups at the End of Cycle 4 (Day 84)…
Febrile Neutropenia
Primary: Mean (SD) Doripenem Pharmacokinetic Volume of Distribution Parameter in Febrile Neutropenic Patients — 36.7; 49.9; 43.9 Liters
Pediatric Acute Myeloid Leukemia
Primary: Compare Differences in HRQOL Scores Between Outpatient Versus Inpatient Management — 70.1; 68.7 score on a scale
Hematopoietic and Lymphoid Cell Neoplasm · Malignant Solid Neoplasm
Primary: Clinical Outcome in the MITT Analysis Set at EOIV. — 44; 37; 5; 12 Participants
Chemotherapy-induced Neutropenia
Primary: Duration of Severe Neutropenia (DSN) — 0.246; 0.770 Days
Neutropenic Complications · Breast Neoplasms · Chemotherapy-induced Neutropenia
Primary: Mean Duration of Severe Neutropenia (DSN) During Cycle 1 of Chemotherapy — 0.75; 0.83; 0.75; 0.79 days — p=0.05
Febrile Neutropenia · Cancer · Breast Cancer
Primary: Chemotherapy Toxicity (%FN Risk) — 154; 650; 640; 3 participants
Acute Myeloid Leukemia · Myelodysplastic Syndrome · Neutropenia
Primary: Number of Participants With Proven or Probable Invasive Fungal Infections (IFIs) — 4 Participants
Chemotherapy-induced Febrile Neutropenia
Primary: Percentage of Investigators Who Ranked Age and Chemotherapy Regimen as a Risk Factor for Febrile Neutropenia — 73.4; 88.3; 41.1; 25.0 percentage of investigators
Neutropenia · Breast Cancer
Primary: Duration of Severe Neutropenia (DSN) in Cycle 1 — 0.31; 0.39 Days — p=< 0.0001
Breast Cancer · Neutropenia
Primary: Duration of Grade 3 or 4 Neutropenia (ANC <1.0×10^9/L) in Cycle 1 — 0.68; 0.71 days
Bone Marrow Failure Syndromes · Immunodeficiencies · Immune Dysregulation Syndromes
Primary: Number of Participants With Engraftment — 2 Participants
Neuroblastoma
Primary: Incidence of Infection — 6 infections
Other Infectious Diseases
Primary: Number of Participants With Favorable Clinical Response at End of Inpatient Intravenous Therapy (EOIV) — 41; 36 Participants
Acute Myeloid Leukemia · Myelodysplastic Syndrome
Primary: Number of Participants With Donor Neutrophil Engraftment — 3; 7; 1 Participants
Anemia, Aplastic · Red-Cell Aplasia, Pure · Anemia, Diamond-Blackfan
Primary: Response to Rituximab — 0; 2; 9 participants
Mycoses
Primary: Incidences of Invasive Fungal Diseases (IFD) — 11.76; 10.14; 23.19 percentage of partipants